<DOC>
	<DOCNO>NCT02182453</DOCNO>
	<brief_summary>Study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics BI 10773 administer healthy Japanese male subject single rise oral dos ( 1 , 5 , 10 , 25 , 100 mg ) .</brief_summary>
	<brief_title>Single Rising Oral Doses BI 10773 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Healthy male volunteer meet follow criterion : Without clinically remarkable finding clinically evident complication base concurrent illness , past medical history , physical examination , vital sign ( blood pressure , pulse rate , body temperature ) , 12lead ECG , laboratory test result Age ≥20 Age ≤35 year Body Mass Index ( BMI ) ≥18.0 ≤25.0 kg/m2 Persons willing participate trial give write consent study initiation accordance Good Clinical Practice ( GCP ) Any find medical examination ( include blood pressure , pulse rate , body temperature , ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( ≥24 hour ) within least one month le 10 halflives respective drug administration investigational product trial Use drug within 10 day administration investigational product trial Participation another trial investigational drug within four month administration investigational product trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse Drug abuse Blood donation ( 100 mL ) within four week administration investigational product trial Excessive physical activity within one week administration investigational product trial Basically , patient laboratory value outside reference range clinical site exclude form study . However , principal investigator see problem subject enter study base result assessment physical examination clinical examination , subject able participate study . In regard , however , subject meet one follow criterion exclude study : FPG ( Fasting plasma glucose ) ≥110mg/dL eGFR ( estimate glomerular filtration rate ) &lt; 60 abnormal value urinalysis Inability comply dietary regimen study centre A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor TdP ( torsade de pointes ) ( e.g. , heart failure , hypokalemia , family history long QT syndrome ) Samsung2014 Renal glucosuria elevate urinary glucose level screen ( &gt; 15 mg/dl ) Any abnormal finding Kidney patient history renal disease Any clinical condition investigator subinvestigator judge subject ineligible study participation</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>